Menu
Search
|

Menu

Close
X

Denali Therapeutics Inc DNLI.OQ (NASDAQ Stock Exchange Global Select Market)

22.40 USD
-0.02 (-0.09%)
As of Feb 23
chart
Previous Close 22.42
Open 22.73
Volume 80,279
3m Avg Volume --
Today’s High 23.12
Today’s Low 22.00
52 Week High 25.50
52 Week Low 14.80
Shares Outstanding (mil) 87.98
Market Capitalization (mil) 1,970.74
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
EPS (USD)
FY17
-0.265
FY16
-0.606
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
--
8.35
Price to Book (MRQ)
vs sector
--
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
--
13.63
Return on Equity (TTM)
vs sector
--
15.39

EXECUTIVE LEADERSHIP

Marc Tessier-Lavignec
Chairman of the Board, Co-Founder, Since
Salary: --
Bonus: --
Ryan Watts
President, Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: --
Bonus: --
Alexander Schuth
Co-Founder, Chief Operating Officer, Head of Corporate Development, Since
Salary: --
Bonus: --
Steve Krognes
Chief Financial Officer, Since
Salary: --
Bonus: --
Carole Ho
Chief Medical Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

151 Oyster Point Blvd Fl 2
SOUTH SAN FRANCISCO   CA   94080-1910

Phone: +1650.8668548

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

SPONSORED STORIES